research use only
Cat.No.S8605
| Related Targets | EGFR JAK Pim |
|---|---|
| Other STAT Inhibitors | Napabucasin (BBI608) Stattic NSC 74859 (S3I-201) Cryptotanshinone (Tanshinone C) SH-4-54 BP-1-102 AS1517499 Nifuroxazide HO-3867 Homoharringtonine (HHT) |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| Y79 | Function assay | 10 μM | 28684419 | |||
| SK-N-DZ | Function assay | 10 μM | 28684419 | |||
| Huh7 | Cell viability assay | 48 h | IC50=11.27 μM | 28533225 | ||
| PLC/PRF/5 | Cell viability assay | 48 h | IC50=11.83 μM | 28533225 | ||
| HepG2 | Cell viability assay | 48 h | IC50=10.19 μM | 28533225 | ||
| SCC-35 | Cell growth assay | 0/0.1/0.3/1/3/10/100 μM | 36 h | IC50=10.8 ± 0.0 μM | 27027445 | |
| SCC-61 | Cell growth assay | 0/0.1/0.3/1/3/10/100 μM | 36 h | IC50=14.8 ±2.9 μM | 27027445 | |
| UM-SCC-17B | Cell growth assay | 0/0.1/0.3/1/3/10/100 μM | 36 h | IC50=0.7 ± 0.6 μM | 27027445 | |
| HN30 | Cell growth assay | 0/0.1/0.3/1/3/10/100 μM | 36 h | IC50=4.4 ± 0.1 μM | 27027445 | |
| A549 | Function assay | 2.5 h | decreased pSTAT3 levels in a concentration-dependent manner starting at concentrations as low as 3 nM | 26410177 | ||
| Kasumi-1 | Function assay | IC50=4.5 μM | 21447830 | |||
| THP-1 | Function assay | IC50=4.8 μM | 21447830 | |||
| GDM-1 | Function assay | IC50=5.0 μM | 21447830 | |||
| NB-1 | Function assay | IC50=8.3 μM | 21447830 | |||
| HL-60 | Function assay | IC50=5.3 μM | 21447830 | |||
| KG-1 | Function assay | IC50=4.1 μM | 21447830 | |||
| K562 | Apoptosis assay | induction of apoptosis with an EC50 of 43.6 μM | 21447830 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 94 mg/mL
(199.35 mM)
Ethanol : 2 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 471.52 | Formula | C27H21NO5S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 432001-19-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | TTI 101 | Smiles | COC1=CC=C(C=C1)S(=O)(=O)NC2=CC(=C(C3=CC=CC=C32)O)C4=C(C=CC5=CC=CC=C54)O | ||
| Targets/IC50/Ki |
STAT3
(Cell-free) 4.7 nM(Kd)
|
|---|---|
| In vitro |
C188-9 is a small-molecule inhibitor of Stat3 that targets the phosphotyrosyl peptide binding site within the Stat3 Src homology 2 (SH2) domain with Ki 136 nM. It does not inhibit upstream Jak or Src kinases.
|
| In vivo |
Treatment of nude mice bearing xenografts of UM-SCC-17B, a radioresistant HNSCC line, with C188-9, but not C188, prevented tumor xenograft growth. This compound was well tolerated in mice, showed good oral bioavailability, and was concentrated in tumors.
|
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | p-STAT3 / STAT3 / CEBPδ / Myostatin / p-Akt / Akt |
|
24011072 |
| Immunofluorescence | VE-cadherin / β-catenin non-phosphorylated β-Catenin |
|
26948077 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.